735 - A case series of dupilumab for vitiligo and alopecia areata in the setting of AD

This case series explores the use of dupilumab, an IL-4/IL-13 inhibitor, in patients with atopic dermatitis (AD) who also have alopecia areata (AA) or vitiligo. The study reviewed seven patients, including six with alopecia universalis (AU) and one with vitiligo and AA. Results showed that dupilumab led to hair regrowth in half of the AU patients and significant repigmentation in the vitiligo patient, suggesting a shared pathogenesis involving IL-4/IL-13 hyper-reactivity. The findings support the potential of dupilumab as a treatment for these conditions, especially in cases where AD overlaps with AA or vitiligo. However, some reports indicate that dupilumab may induce or worsen vitiligo, highlighting the need for further research, particularly in children under 12 who lack approved systemic treatments for vitiligo and AU.